This article describes an objective evaluation of six thyrotropin (TSH) kits. One was a radioimmunoassay kit taken for comparison, three were immunoradiometric assays and one was an immunoenzymometric assay. The laboratory internal immunoluminometric assay for thyrotropin was used to measure the concentrations of thyrotropin in the kit Standards using a Standard curve of WHO 68/38 international reference preparation in serum from a thyrotoxic patient äs matrix. The in-house assay was used to demonstrate the "sensitivity" to citrated plasma and the fact that kit Standards could only measure "correctly" when used in its own kit.
Introduction
came. In addition, to increase the objectivity, eacĥ . t , kit producer whose product was included in the study Dunng recent months, an mcreasmg number of sens.-wa$ invited to send a Ufied technician t0 form
Uve thyrotropin assay kits has appeared on the ^ ^ so ^ ^ of ^ ducer ftat tfae market and several reports of the performance of pers(jns carrying ^ ^ ^ werß ^ inted such lots have already been pubhshed (l -4). ^ .^ therefore ^ ^^ wefe ^ optimalj Ô n the clinical side, the question has been raised äs * edttded. ™» <*te was taken up in the case of to whether such sensitive kits may alleviate the major, 4 /rom the 6 kits tested. The fact that the laboratory ity of thyroliberin (TRH) Stimulation tests at present of the autho^ was not concerned with the routine mcarried out to detect borderline hyperthyroidism Vltro *yroid-P ituitary axis diagnosis removed the (1_ \ possibihty of being influenced by the in-house routine method. In fact the laboratory^own method, an imThe present study was carried out in order to provide munoluminometric assay for thyrotropin (5) was only an answer, if possible, to the latter question. The used-to compare the Standards from all kits in an study was organised in a "blind" way, so that the independerit assay äs well äs to demonstrate the analyst only received numbered sera and had no idea · difference in results obtained from serum and citrated from what sort of patients or control groups these plasma saniples. J It was not sufficient to have a sensitive kit, äs far äs the Standard curve was concerned, and the nature of the study allowed an evaluation of each kit's ability to differentiate between euthyroid and untreated hyperthyroid patients, äs well äs to establish, when in a limited way, expected reference ranges for these two groups of patients.
Materials and Methods
The following thyrotropin kits were included in the study and allotted the codes used throughout the rest of the publication: Kits A and D used the 2nd IRP-TSH preparation (NIBSC 80/558) for calibration, the rest, the WHO 68/38 reference material to calibrate the kit Standards.
The house-internal immunoluminometric assay was performed äs already published (5) and is included äs method G, where used. Table l shows the main points of the six kits used äs far äs components and total assay time are concerned. More detailed Information on the assay schemes äs performed in this study are to be seen in table 2.
Radioactivity was counted in a 16-well gamma spectrometer (counting efficiency 0.74-0.76) (Nuclear Enterprises, Sighthill, OB) data being reduced off-line with a CBM 8296 desk-top Computer (Commodore Business Machines, Frankfurt a;n Main, D) using a spline function with automatic smoothing factor. All data were processed with this programme.
The colorimetric determination of kit E was performed on an ES-11 photometer coupled on-or off-line to an Epson HX-20 mini-computer (Boehringer-Mannheim).
The luminescence measurements were made on a LKB-1251 25-sample luminometer (LKB-Wallac, Turku, SR), data reduction being -line with the spline function described above.
All assays were performed exactly äs stated in the kit instructions, except for kit D, where two wash Steps were performed before radioactivity counting. In kit D, half the samples were decanted äs stated in the instructions, the other half were carefully aspirated off using the set-up present in the laboratory and used for all routine radioimmunoassays performed in this laboratory. Kit E was performed with the normal reagents, but with a modified procedure lo improve sensitivity. Kits A, C and E were not commercially available at the time of testing but should be on the market in the first half of 1985 according to manufacturers' Claims in the form here tested.
Statistics were kept to a minimum, mainly using non-parametric methods, namely the Mann-Whitney U-Test for comparison of two unrelated samples and the Wilcoxon rank test for paired data. Other data are given in terms of the relevant percentiles and median. Correlations using the paired t-test were made on the euthyroid reference collectives, using kit A äs the reference method, this because kit A had the lowest number of sera in which the thyrotropin-concentration was below the detection limit (one serum sample). The experimentai groups tested were s follows:
Group I -Sera from 51 non-screened blood donors.
Group II -Citrated plasma from 49 non-screened blood donors (not identical with those in group I).
Group III *-thyroliberin-test sera before and 30 minutes after 200 μg Protirelin iv. (Antepan-200®, Henning Berlin), in 12 supposedly euthyroid laboratory personnel, 5 untreated hyperthyroid patients and l hypophysectomised patient.
Group IV -Sera from 41 patients attending the thyroid outpatient clinic in the Medizinische Hochschule L beck during November 1984. The patients were not selected, the only criterium being the consent of the patient to take part in the study.
All assays were performed in the first half of December 1984 using 2 batches of reagents for eaeh method. Kits B, C, D and F were carried out by repr sentatives of the respective firms to guarantee optimal results. Kit A was tested by the author and kit E by a technical assistent in the laboratory of the author.
Results
Figure l shows the distribution of results for groups I and II, the non-screened blood donors, serum and plasma values respectively. The 16th, SOth.and 84th percentiles are shown together with the ranges. In group I 3 blood donors were found to be hyperthyroid and l blood donor to be hypothyroid, using serum thyroxine (T 4 ), thyroxine binding globulin (TBG) and the T 4 : TBG rati s criteria.
Kits A, C, D and E recognised all four cases correctly. Kits B and F recognised the hypothyroid case. Kit B was unable to recognise any of the hyperthyroid cases and Kit F failed to detect two of the hyperthyroid cases. Blood -donors citrated plasma n = 49 Figure 2 shows the results of group III, the thyroliberin tests on 12 laboratory personnel and on 5 non-treated hyperthyroid patients and l hypophysectomised patient. The hypophysectomised patient (Patient 3 of the second group in figure 2) showed paradoxical results. In Kits A and D, no response to thyroliberin was seen, whereas in the other kits, all showed a measureable thyrotropin increase after thyroliberin. Figure 3 shows the distribution of the individual values from group IV, the thyroid outpatient clinic patients. Individual results are presented to allow a comparison between kits for each patient s measured in each of the 6 kits. represents the lower detection limit of all kits. The small numbers each represent a proband, the larger numbers the thyrotropin value for probands lying outside the concentration on the respective Ordinate. In Kit C proband No 4 had been treated some years before with a rat-serum antibody to yellow fever. No other cause for the repeatedly high values could be found. of the assay. NS 14 -Affmity extracted human serum using solidrphase polyclonal anti-thyrotropin TSHFS -äs NS 14 but using an alpha-specific monoclonal anti-thyrotropin 9040 -Serum from an untreated hyperthyroid patient with a thyroxineithyroxine binding globulin ratio above 10. Table 4 shows the performance of all kits in measuring 5 poolsera and a hyperthyroid patient serum (9040), the latter having a thyroxine: thyroxine binding globulin ratio above 10. Sera NS 14 and TSHFS had been rendered "TSH-free" with affinity chromatography using polyclonal (NS 14) and alphaspecific monoclonal antibodies (TSHFS). Figure 4 shows the compound precision profiles (5, 6) for all samples measured within the concentration ränge lower detection limit to 5mU/l thyrotropin, each decile representing 0.5 mU/1. The results are taken from 10 assays from each kit. Table 5 shows the intra-assay coefficients of Variation for different sera and kit control sera covering the ränge up to 12 mU/1 thyrotropin. and show the i herent dangers of trying to use Standards from kit χ in kit y. Table 7 shows the correlation of the e thyroid patients in table 4 using Kit A s x-value, this because Kit A had pnly ,a single senim in the whole study which lay below the lower detection limit, no other kit being able to match this performance. 
Djscussion
Although it was and is not the aim of this study to exalt or condemn, it is clear that the days of the conventional radioimmunoassay are numbered where a rapid discrimination between euthyroid and hyperthyroid patients is concerned, even when such assays claim to be supersensitive, but take 4 days to produce results (4) . The specificity of radioimmunoassays for hormones such äs thyrotropin is questionable äs all fragments and aggregation products containing the epitopes recognised by the antibody are bound and can give rise to falsely elevated results.
The new immunometric assays based completely or partly upon monoclonal antibodies herald a new era in thyroid diagnosis and surveillance. At the same time, new problems have been presented to the kit producer, especially in the production of an acceptable thyrotropin-free matrix for the Standards, and it may be, that the tenets upheld by this group for several years, (8, 9) i. e. thyrotropin Standards dissolved in thyrotropin-free human serum, may now no longer be practical in assays capable of measuring under 0.05 mU/1 thyrotropin. That the Standard matrix is different in each kit can be seen in the results from electropherograms which have not been presented here, but in which the total protein and albumin: globulin ratios were often highly abnormal. One kit (Kit F) used a non-human based matrix for the Standards. and Kit D for the euthyroid patients (tab. 7), does not detract from the fact that the slope of the regression curve shows results which differ by 30%. Such a differerice in values was not expected äs both kits used Standards calibrated against the 2nd IRP -(NIBSC 80/558). This shows that kits must be optimally calibrated to give similar values, even if the matrix is not "pure" thyrotropin-free human serum and the secondary (calibration) Standard not identical with the WHO reference preparation, which is the case in all kits. The degree of "thyrotropin-freeness" must be seen with respect to the epitopes on the antibodies used, and it may be that a matrix is thyrotropin-free in one System, but not in another (see tab. 5 and 6 -sera NS 14 and TSHFS).
One of the main points emerging from this study was the excellent precision and sensitivity of certain kits coupled with a short incubation time of äs little äs 2 h (Kit A). Even setting up an assay with 300 tubes using this kit in which the pipetting of serum took 110 minutes did not influence the kit performance in terms of the Standard curve and control serum values from the end of the assay read off the Standard curve at the beginning of the assay and vice versa. Another interesting result was that the overnight version of the enzyme-labelled assay (Kit E) was äs sensitive äs the immunoradiometric tests. This allows the complete thyroid in-vitro diagnosis (with the possible exception of thyroglobulin) to be performed with commercially available non-radioactively labelled techniques. Even though the ränge of Kit E was relatively small (0 -6 mU/1 thyrotropin) in the overnight version, this is large enough for the initial differentiation between hyperthyroid, euthyroid and hypothyroid patients. The same-day version of Kit E allows the ränge 0.2-50 mU/1 thyrotropin to be covered.
The hypophysectomised patient gave rise to int eresting thyrotropin values before and after thyroliberin-test. Although all immünometric tests claimed to raeasure "intact-thyrotropin", the degree of "intactness" was different äs Kits A and D showed no response to thyroliberin, whereas Kits D, E and F showed a marked response of "thyrotropin" to thyroliberin-stimulation. These results remain paradoxical, especially in terms of the therapy chosen, but serve äs an example that even in these kits "thyrotropin" is not always thyrotropin! (10)
The kit with the most complicated and somewhat clumsy methodology (Kit F) gave rise to the worst results with respect to inter-and intra-assay precision, even in the hands of the technician from the firm offering the kit (fig. 4 , Tab. 5-7). These results confirm earlier reports with this kit (11) . Kit F exaggerated its Claims to sensitivity äs it was unable in many cases to differentiate between untreated hyperthyroid patients and clinically euthyroid patients and occupied the penultimate place before the conventional RIA (Kit B) with regard to this point. The sensitivity of the assay on paper cannot be treated separately from the ability to differentiate between the groups in question. The differing results from Kit F may reflect the non-human Standard matrix to some extent.
The kit with the largest dynamic ränge (signal ratio highest Standard: zero Standard (signal to noise ratio)) was Kit A, followed by Kit E (in the ränge 0-6 mU/1 thyrotropin). Both these kits had a low signal in the zero Standard (see tab. 7). Table 7 also shows the main drawback of the immunoradiometric technology, namely the large amounts of radioactivity present in the kits, this being in certain cases 10-fold that in the conventional RIA (Kit D 209 200 counts/ min · 100 , Kit B 22400 counts/min · 100 ), a point which must be taken into aecount when operating with a licence allowing a limited amount of 125 I. The immunoradiometric assay kit with the lowest activity was Kit F which had only a quarter of the radioactivity in Kit D. The precision profiles showed that kit A had the best precision profile although Kits A, D and E had excellent precision in the ränge 0.5 -5 mU/1 thyrotropin (fig. 4) . This confirms the data published by Hunter (6) who showed that inl·· munometric assays should give a better precision profile than radioimmunoassays.
On the other band, the most stable curve form (tab. 6) was exhibited in kits C, D, and E. The latter point may play a role in curve-fitting procedures where a Computer Software package is used in which the user has little or no chance to alter the routines to suit the assays used. Figure l shows that the kits were not affected by calcium-free plasma, in contrast to the in-house assay (Method G) which reacted allergically to plasma when using a certain labelled second antibody. Replacernent of the label removed the anomalous effects without äffecting the sensitivity of this assay. This test was carried out äs it is ofteri stated that certain antibodies are "plasma" or "calcium" sensitive (12).
All immünometric methods gave similar euthyroid reference ranges, when the ealibration preparation is taken into aecount. This ränge appears to be smaller than that given for the RIA (13) (14) (15) and to that given in some of the kit protocols (Kits D and F). As Kits A, C and E were still not available commercially, the protocols being somewhat ad-hoc in nature and not containing relevant clinical data, it was impossible to compare the ranges here found with those in the kit instructions. The narrower (and lower) euthyroid ranges may reflect the improved specificity of the kits in measuring "intact" thyrotropin.
Figures 2 and 3 were included to show that each kit retains some "individuality" with respect to serum values from each patient, which means that the established präctice of chöosing a kit äs the laboratory method still holds, even when the overall results tend towards more homögeneous and comparable reference ranges. In figure 2 patient 4 of the euthyroid group gave anomalous results inasrnuch äs the thyroid Status was normal büt the basal thyrotropin with kit C was above 50 mU/1! One possible explanation could be that the pf obänd had been treated with rat-serum for yellow fever several years befofe, and that interfering antibodies were present. This was ' partially supported by the fact that when the incubation buffer was changed this #nomaly disappeared, basal thyrotropin being 0.6 mU/1, the stimulated value 12.9 mU/1, which agreed with the results from other kits. As a result of these findings, the assay buffer of Kit C was changed by the producer accordingly.
The era of monoclonal antibodies should make the long-term comparison of results better inasmuch äs the reagents are standardised and available in large amounts suitable for production over several years. Moreover it is possible to choose epitopes on the thyrotropin molecule which will only measure the intact molecule. The change from radioactive to nonradioactive labelling techniques should allow the change to alternative methodology without having to worry about comparison of results.
The need for a "conventional" thyroliberin-test will be much reduced due to increased sensitivity and better differentiation of eu-and hyperthyroid patients with the new immunometric assays for thyrotropin. The degree of the reduction in thyroliberin-tests must be awaited in terms of clinical practice, where other in-vitro and clinical parameters are used to make up the complete diagnostic picture. Finally, the thyroliberin-test receives a new and interesting role, namely the monitoring of returning pituitary-thyroid axis interplay under therapy of thyrotoxic patients, äs all immunometric kits were able to measure a thyrotropin difference of 0.5 mU/1 in the ränge 0 -1 mU/1. With the advent of sensitive and precise thyrotropin kits a new era in in-vitro thyroid surveillance is dawning.
